Growing evidence for survival benefit with plasma exchange to treat liver failure

Plasma exchange (PLEX) to treat liver failure patients is gaining increasing momentum in recent years. Most reports have used PLEX with acute (ALF) or on chronic (ACLF). Etiology of disease has an important bearing the prognosis illness these patients. The accruing data suggests survival benefit compared standard medical treatment ALF and ACLF patients, randomised controlled trials done worldover. American College Apheresis now recommends high volume as first line for matched cohort studies from India which recruited a specific etiology report treatment. appears more pronounced rather than Systematic analysis efficacy needed. There also need identify dynamic predictive scores assess will respond PLEX.